Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$19.9 - $26.25 $72,674 - $95,865
-3,652 Reduced 60.34%
2,400 $48,000
Q2 2023

Jul 18, 2023

BUY
$18.95 - $28.67 $58,934 - $89,163
3,110 Added 105.71%
6,052 $154,000
Q1 2023

May 01, 2023

BUY
$20.02 - $31.37 $18,058 - $28,295
902 Added 44.22%
2,942 $62,000
Q4 2022

Feb 07, 2023

SELL
$20.37 - $32.9 $1,222 - $1,974
-60 Reduced 2.86%
2,040 $60,000
Q3 2022

Oct 25, 2022

SELL
$17.49 - $28.44 $6,995 - $11,376
-400 Reduced 16.0%
2,100 $48,000
Q2 2022

Aug 04, 2022

SELL
$12.95 - $46.99 $647 - $2,349
-50 Reduced 1.96%
2,500 $41,000
Q1 2022

Apr 14, 2022

BUY
$40.12 - $59.5 $52,156 - $77,350
1,300 Added 104.0%
2,550 $111,000
Q4 2021

Jan 18, 2022

SELL
$41.7 - $61.14 $557,779 - $817,808
-13,376 Reduced 91.45%
1,250 $76,000
Q3 2021

Oct 26, 2021

BUY
$27.95 - $44.24 $408,796 - $647,054
14,626 New
14,626 $608,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $607M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.